Retroperitoneal lymph node dissection: the past, present, and future, a review
DOI:
https://doi.org/10.52786/isu.a.71Keywords:
Testicular cancer, retroperitoneal lymph node dissection, modified template, nerve-sparingAbstract
Testicular cancer is a malignancy that impacts young men worldwide. The modern treatment of testicular cancer has evolved due to innovations in medical approaches and surgical techniques. The retroperitoneal lymph node dissection (RPLND) is an integral component in the treatment of testicular cancer. We aim to highlight the advances in surgical approaches and oncologic considerations noted over the past century. Once recognized as a highly morbid procedure, innovations in the understanding of anatomy and minimally invasive approaches have greatly improved patient outcomes. In addition to surgical approaches, we describe oncologic principles associated with modern dissection templates for both non-seminomatous germ cell tumors as well as more recent indications for surgery in seminomatous germ cell tumors. The overall goal of this review is to provide a summary in the utility and recent advances in RPLND techniques.
References
Cancer of the Testis - Cancer Stat Facts. NIH SEER [Internet]. [cited 2023 February 22]. Available from: https://seer.cancer.gov/statfacts/html/testis.html
Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Kuliš T, Laversanne M, Gurney J, et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer 2022;151:692-8.
Fung C, Dinh PC, Fossa SD, Travis LB. Testicular cancer survivorship. J Natl Compr Cancer Netw JNCCN 2019;17:1557-68.
Leibovitch L, Foster RS, Kopecky KK, Donohue JP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759-63.
Ray B, Hajdu SI, Whitmore Jr WF. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 1974;33:340-8.
Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128:315-20.
Hendry WF. Retroperitoneal lymphadenectomy in the management of testis cancer. In: Neal DE, editor. Tumours in urology. Springer: London; 1994. p. 273-92.
Hinman F. The operative treatment of tumors of the testicle: with the report of thirty cases treated by orchidectomy. J Am Med Assoc 1914;LXIII:2009-15.
Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol 2003;21:129-32.
Fraley EE, Narayan P, Vogelzang NJ, Kennedy BJ, Lange PH. Surgical treatment of patients with stages I and II nonseminomatous testicular cancer. J Urol 1985;134:70-3.
Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modi- fications of technique and impact on ejaculation. J Urol 1993;149:237-23.
Krege S, Rübben H. [Lymphadenectomy for testicular cancer. Diagnostic and prognostic significance as well as therapeutic benefit]. Urol Ausg A 2005;44:652-6.
Tran V, Gibson L, Sengupta S. Retroperitoneal lymph node dissection for germ cell tumour. Transl Androl Urol 2020;9:3103-11.
Nayan M, Jewett MAS, Sweet J, Anson-Cartwright L, Bedard PL, Moore M, et al. Lymph node yield in primary retroperitoneal lymph node dissection for nonseminoma germ cell tumors. J Urol 2015;194: 386-91.
Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol 2010;28:504-9.
Jewett MAS, Groll RJ. Nerve-sparing retroperitoneal lymphadenectomy. Urol Clin North Am 2007;34: 149-58.
Tanaka T, Kitamura H, Kunishima Y, Takahashi S, Takahashi A, Masumori N, et al. Modified and bilateral retroperitoneal lymph node dissection for testicular cancer: peri- and postoperative compli- cations and therapeutic outcome. Jpn J Clin Oncol 2006;36:381-6.
Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol 2007;177:937-42; discussion 942-43.
Douglawi A, Calaway A, Tachibana I, Barboza MP, Speir R, Masterson T, et al. Long-term oncologic outcomes after primary retroperitoneal lymph node dissection: minimizing the need for adjuvant chemotherapy. J Urol 2020;204:96-103.
Sheinfeld J, DiNatale RG, Carver B. Editorial com- ment. J Urol 2020;204:101-2.
McKiernan JM, Motzer RJ, Bajorin DF, Bacik J, Bosl GJ, Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology 2003;62:732-6.
Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB. Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors. Adv Urol 2018;2018:e8671832.
Kim P, Syan-Bhanvadia S, Djaladat H, Faber K, Tadros NN, Nichols C, et al. Midline extraperitoneal approach for retroperitoneal lymph node dissection for testicular germ cell tumor. Urology 2012;80:941-5.
Syan-Bhanvadia S, Bazargani ST, Clifford TG, Cai J, Miranda G, Daneshmand S. Midline extraperitoneal approach to retroperitoneal lymph node dissection in testicular cancer: minimizing surgical morbidity. Eur Urol 2017;72:814-20.
Davol P, Sumfest J, Rukstalis D. Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 2006;67:199.
Williams SB, Lau CS, Josephson DY. Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer. Eur Urol 2011;60: 1299-302.
Ohlmann CH, Saar M, Pierchalla LC, Zangana M, Bonaventura A, Stöckle M, et al. Indications, feasibility and outcome of robotic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours. Sci Rep 2021;11:10700.
Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, et al. Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. Eur Urol 2017;71:476-82.
Rocco NR, Stroup SP, Abdul-Muhsin HM, Marshall MT, Santomauro M, Christman MS, et al. Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes. World J Urol 2020;38:859-67.
Mittakanti HR, Porter JR. Robot-assisted laparoscopic retroperitoneal lymph node dissection: a minimally invasive surgical approach for testicular cancer. Transl Androl Urol 2020;9:S66-73.
Santomauro MG, Stroup SP, L’Esperance AH, Masterson JH, Derweesh IH, Auge BK, et al. Supine robotic-assisted retroperitoneal lymph node dissection for testicular cancer. CRSLS e2014.00326.
Stephenson A, Eggener SE, Bass EB, Chelnick M, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA Guideline. J Urol 2019;202:272-81.
Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol Off J Am Soc Clin Oncol 2023;41:3009-18.
Hiester A, Che Y, Lusch A, Kuß O, Niegisch G, Lorch A, et al. Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol 2022;S0302-2838(22)02775-0.
Heidenreich A, Paffenholz P, Nestler T, Pfister DA. Nerve sparing retroperitoneal lymph node dissection in clinical stage IIA/B seminoma: The COTRIMS trial. J Clin Oncol 2022;40:418.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Insight Urology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
